Physician profile
Avery Grace Warner
NPI 1770213845
$9,877.63
in general payments reported to CMS, 2019-2025
34 companies · $2,837 in 2025
The $2,837 reported for 2025 was more than what 96% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,143 · 2023: $3,183 · 2024: $2,714 · 2025: $2,837.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,735.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,734.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,187.05 | 2022-2025 | |
| Lilly USA, LLC | $937.52 | 2022-2025 | Mounjaro, Zepbound, Kisunla |
| Astrazeneca Pharmaceuticals LP | $903.06 | 2022-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $809.11 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $588.84 | 2022-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbott Laboratories | $374.35 | 2023-2025 | Freestyle Libre 3 |
| Pfizer INC. | $364.60 | 2023-2025 | |
| Antares Pharma, INC. | $341.31 | 2022-2025 | Xyosted, Nocdurna, Tlando |
| Phathom Pharmaceuticals, INC. | $332.51 | 2024-2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $257.69 | 2022-2025 | Jardiance, Tradjenta |
| Otsuka America Pharmaceutical, INC. | $248.41 | 2023-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $205.77 | 2022-2025 | Spravato |
| Axsome Therapeutics, INC. | $197.97 | 2024-2025 | Auvelity |
| Biohaven Pharmaceutical Holding Company LTD. | $129.03 | 2022 | |
| Astellas Pharma US INC | $111.48 | 2025 | Veozah |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $111.21 | 2023-2024 | Hillrom - Carnation Ambulatory Monitor |
| Leo Pharma INC. | $104.10 | 2024 | Adbry |
| Novartis Pharmaceuticals Corporation | $86.37 | 2022-2023 | |
| Exact Sciences Corporation | $74.00 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Amgen INC. | $56.53 | 2024-2025 | Repatha, Repatha |
| Vertex Pharmaceuticals Incorporated | $49.62 | 2024-2025 | |
| Kowa Pharmaceuticals America, INC. | $47.79 | 2023-2024 | Livalo, Seglentis |
| Currax Pharmaceuticals LLC | $47.41 | 2023-2025 | Contrave |
| Corium, LLC | $44.63 | 2024 | Azstarys |
| E.R. Squibb & Sons, L.L.C. | $42.98 | 2023 | Eliquis |
| Madrigal Pharmaceuticals | $39.36 | 2025 | Rezdiffra |
| Corcept Therapeutics | $34.42 | 2023 | Korlym |
| Collegium Pharmaceutical, INC. | $33.73 | 2025 | Jornay Pm |
| Halozyme INC | $23.26 | 2023 | |
| Boston Scientific Corporation | $22.64 | 2024 | Bodyguardian |
| Si-Bone, INC. | $20.68 | 2025 | |
| Actelion Pharmaceuticals US, INC. | $19.68 | 2025 | Uptravi, Opsumit |
| Dexcom, INC. | $17.40 | 2023 | Dexcom G6 Transmitter |
| Sanofi Pasteur INC. | $13.12 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Avery Warner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.